An audit of the results of a triplet metronomic chemotherapy regimen incorporating a tyrosine kinase inhibitor in recurrent/metastatic head and neck cancers patients

An audit of the results of a triplet metronomic chemotherapy regimen incorporating a tyrosine kinase inhibitor in recurrent/metastatic head and neck cancers patients

Background: Addition of erlotinib to metronomic chemotherapy (MCT) may lead to further improvement in progression-free survival (PFS) and overall survival in head and neck cancers. The aim of this study was to study the PFS with MCT + erlotinib combination in our setting. Methods: A single-arm prosp...

Full description

Bibliographic Details
Main Authors: Vijay M Patil, Santam Chakraborty, T K Jithin, T P Sajith Babu, Satheesh Babu, Shiva Kumar, M S Biji, Atanu Bhattacharjee, Satheesan Balasubramanian
Format: Article
Language:English
Published: Thieme Medical and Scientific Publishers Pvt. Ltd. 2016-01-01
Series:South Asian Journal of Cancer
Subjects:
Erlotinib
head and neck cancer
metronomic administration
palliative chemotherapy
Online Access:http://journal.sajc.org/article.asp?issn=2278-330X;year=2016;volume=5;issue=2;spage=48;epage=51;aulast=Patil

Internet

http://journal.sajc.org/article.asp?issn=2278-330X;year=2016;volume=5;issue=2;spage=48;epage=51;aulast=Patil

Similar Items